TABLE 4.

Risk stratified linear regression models^*

Covariate	Overall cohort (n = 3056)		CAPRA low risk (n = 1804)		CAPRA intermediate risk (n = 956)		CAPRA high risk (n = 266)
	Coefficient	P	Coefficient	P	Coefficient	P	Coefficient	P
Number of comorbidities	−0.73	0.04	−0.67	0.13	−1.08	0.06	0.16	0.9
SF-36 MCS	0.14	< 0.01	0.17	< 0.01	0.15	0.14	0.1	0.59
SF-36 PCS	0.13	0.02	0.2	< 0.01	0.14	0.11	0.05	0.8
FCR	−0.16	< 0.01	−0.17	< 0.01	−0.12	< 0.01	−0.14	0.19
PCI SF decline	−1.81	0.04	−1.83	0.11	−1.16	0.45	−4.61	0.17
PCI UF decline	−2.84	< 0.01	−2.92	0.02	−2.39	0.16	−0.57	0.87
PCI BF decline	−2.15	0.02	−1.83	0.09	−3.27	0.03	−0.13	0.97

^*Adjusted for age, education, ethnicity, relationship status, treatment type, number of office visits per year, time to treatment, type of clinical facility and body mass index.

BF, bowel function; CAPRA, Cancer of the Prostate Risk Assessment; FCR, fear of cancer recurrence; MCS, Mental Component Summary; PCI, Prostate Cancer Index; PCS, Physical Component Summary; SF, sexual function; SF-36, 36-item short-form health survey; UF, urinary function.